BSE filing, NSE: BLISSGVS. Summary written from the filing by ALFA Finder's alert engine.
Bliss GVS Pharma Ltd: key numbers
- Share price
- ₹652.75
- Market cap
- ₹6,944 Cr
- Revenue (annual)
- ₹927.1 Cr
- Net profit (annual)
- ₹129.1 Cr
- P/E (TTM)
- 51.0×Sector 46.5×
- Promoter holding
- 50.07%+15.06% QoQ
- FII holding
- 5.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bliss GVS Pharma Ltd
All →Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma seeks shareholder approval via postal ballot for new employee stock option plans 2026. Up to 26,50,000 options are proposed; voting closes November 27, 2026.
Bliss GVS Pharma Board Meeting Date
Bliss GVS Pharma Ltd scheduled a board meeting for October 29, 2026, to approve the company's unaudited financial results for the quarter ending September 30, 2026.
Bliss GVS Pharma Annual General Meeting
Bliss GVS Pharma has issued a postal ballot notice to seek member approval for the appointment of three directors. This follows a recent change in control.
Bliss GVS Pharma Employee Stock Options
Bliss GVS Pharma Limited allotted 53,500 equity shares under its Employee Stock Option Plan (ESOP). This issuance increases the company's total paid-up share capital.
Bliss GVS Pharma Promoter Reclassification
Bliss GVS Pharma announced the reclassification of its erstwhile promoter group to the public category following a change in control via an open offer.
Bliss GVS Pharma Share Pledge
Promoter Mates Visa Consultancy pledged 5.1 crore shares of Bliss GVS Pharma valued at ₹3,487.35 Crore. This pledge creates leverage on the promoter's stake.
- Value
- ₹3,487 Cr
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.